Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.46 |
| ▸ | FNTA | P49354 | 3/20 | 0.45 |
| ▸ | FNTB | P49356 | 3/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7303552 | 0.87 | CTSC (0.48) | CTSCFNTAFNTBPGGT1BTSHR | |
| SCHEMBL7375880 | 0.84 | OPRM1 (0.51) | SLC6A9SLC6A5TSHRF7 | |
| SCHEMBL30052536 | 0.81 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL7370114 | 0.81 | SLC6A9 (0.49) | SLC6A9SLC6A5TSHRF7 | |
| SCHEMBL7317840 | 0.80 | CTSC (0.51) | MMP2CTSCFNTAFNTBPGGT1B | |
| SCHEMBL7371275 | 0.80 | SLC6A9 (0.53) | SLC6A9SLC6A5TSHRF7 | |
| Hydrochloric Acid SCHEMBL11327258 | 0.79 | OPRD1 (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL7305453 | 0.79 | CNR1 (0.57) | CTSCFNTAFNTBPGGT1B | |
| SCHEMBL13927675 | 0.79 | CTSC (0.50) | MMP2CTSCFNTAFNTBPGGT1B | |
| SCHEMBL7313421 | 0.78 | POLB (0.55) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994027958-A1 | 4-AMIDINOPHENYLSULPHONAMIDES FOR THE TREATMENT OF THROMBO-EMBOLITIC CONDITIONS | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-08 | — | — | WO | disclosed |